86% of $36 million EB-5 Phase I Funding Received by the Company; EB-5 Financing is Repaying 14% High Cost Bridge Loan with 3% Low Cost, Long Term Funding
CUPERTINO, CA / ACCESSWIRE / October 24, 2016 / Aemetis, Inc. (NASDAQ: AMTX), an advanced fuels and renewable chemicals company, announced that $6 million has been received from EB5 funding, resulting in 86% of the $36 million EB-5 Phase I funding having been received by the company. The $6 million repays the existing 14% interest rate bridge loan with 3% interest rate, long term EB-5 funding.
Under the EB-5 Phase I funding, Aemetis offered subordinated notes in the amount of $500,000 per note to refinance the high interest rate bridge loan for the existing Keyes ethanol plant, and raised $36 million from 72 foreign investors. To date, $31 million of this amount has been released from the EB-5escrow account to the company and used to reduce a higher cost bridge loan held by our senior lender. After applying the $6 million, the senior bridge loan reduced to $62.5 million.
With an EB-5 project track record established, Aemetis recently commenced a $50 million Phase II funding in September 2016. Aemetis' financing plan is to repay its high cost senior bridge loan with low cost EB-5 funding and funds from operations. This repayment of the senior bridge loan is expected to result in significant interest rate savings.
About Aemetis, Inc.:
Headquartered in Cupertino, California, Aemetis is an advanced fuels and renewable chemicals company founded in 2006. Aemetis owns and operates a 60 million gallons per year ethanol and 420,000-ton animal feed plant in California. Aemetis also owns and operates a 50-million-gallon capacity renewable chemicals and advanced fuels production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia. Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds granted patents on technology for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.
Safe Harbor Statement:
This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements regarding our business plans, growth opportunities, our ability to meet our funding goals under the EB-5 Phase II funding, our expectations regarding the timing of the receipt of funds from escrow and our expected cost savings from repayment of our senior bridge loan. Words or phrases such as "anticipates," "may," "will," "should," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, completion of the terms of the agreement, completion of the EB-5 financing transactions, financial market risks, counter-party risks, risks associated with changes to government policy or regulation, and other risks detailed in our reports filed or to be filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2015 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.
External Investor Relations Contact:
PCG Advisory Group
Company, Investor Relations & Media Contact:
SOURCE: Aemetis, Inc.